IRIS Accounts Production v25.4.0.155 12804340 director 1.7.24 30.6.25 30.6.25 19.2.26 false true false false true false Auditors Opinion Ordinary 1.00000 iso4217:GBP iso4217:USD iso4217:EUR xbrli:shares xbrli:pure utr:tonnes utr:kWh 12804340 2024-06-30 12804340 2025-06-30 12804340 2024-07-01 2025-06-30 12804340 2023-06-30 12804340 2023-07-01 2024-06-30 12804340 2024-06-30 12804340 ns15:EnglandWales 2024-07-01 2025-06-30 12804340 ns14:PoundSterling 2024-07-01 2025-06-30 12804340 ns10:Director1 2024-07-01 2025-06-30 12804340 ns10:PrivateLimitedCompanyLtd 2024-07-01 2025-06-30 12804340 ns10:SmallEntities 2024-07-01 2025-06-30 12804340 ns10:Audited 2024-07-01 2025-06-30 12804340 ns10:SmallCompaniesRegimeForDirectorsReport 2024-07-01 2025-06-30 12804340 ns10:SmallCompaniesRegimeForAccounts 2024-07-01 2025-06-30 12804340 ns10:FullAccounts 2024-07-01 2025-06-30 12804340 ns10:OrdinaryShareClass1 2024-07-01 2025-06-30 12804340 1 2024-07-01 2025-06-30 12804340 ns10:RegisteredOffice 2024-07-01 2025-06-30 12804340 ns5:CurrentFinancialInstruments 2025-06-30 12804340 ns5:CurrentFinancialInstruments 2024-06-30 12804340 ns5:Non-currentFinancialInstruments 2025-06-30 12804340 ns5:Non-currentFinancialInstruments 2024-06-30 12804340 ns5:ShareCapital 2025-06-30 12804340 ns5:ShareCapital 2024-06-30 12804340 ns5:FurtherSpecificReserve2ComponentTotalEquity 2025-06-30 12804340 ns5:FurtherSpecificReserve2ComponentTotalEquity 2024-06-30 12804340 ns5:RetainedEarningsAccumulatedLosses 2025-06-30 12804340 ns5:RetainedEarningsAccumulatedLosses 2024-06-30 12804340 ns5:PlantMachinery 2024-06-30 12804340 ns5:PlantMachinery 2024-07-01 2025-06-30 12804340 ns5:PlantMachinery 2025-06-30 12804340 ns5:PlantMachinery 2024-06-30 12804340 ns5:CostValuation 2024-06-30 12804340 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2025-06-30 12804340 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2024-06-30 12804340 ns10:OrdinaryShareClass1 2025-06-30 12804340 ns5:RetainedEarningsAccumulatedLosses 2024-06-30 12804340 ns5:FurtherSpecificReserve2ComponentTotalEquity 2024-06-30 12804340 ns5:RetainedEarningsAccumulatedLosses 2024-07-01 2025-06-30

REGISTERED NUMBER: 12804340 (England and Wales)

| FINANCIAL STATEMENTS |

| FOR THE YEAR ENDED 30 JUNE 2025 |

| FOR |

| HARRISON-AI MEDICAL UK LTD |

| PREVIOUSLY KNOWN AS |

| ANNALISE-AI UK LTD |

HARRISON-AI MEDICAL UK LTD (REGISTERED NUMBER: 12804340)

PREVIOUSLY KNOWN AS ANNALISE-AI UK LTD

CONTENTS OF THE FINANCIAL STATEMENTS

for the Year Ended 30 June 2025

Page |

| Company Information | 1 |

| Balance Sheet | 2 |

| Notes to the Financial Statements | 3 |

HARRISON-AI MEDICAL UK LTD

PREVIOUSLY KNOWN AS ANNALISE-AI UK LTD

COMPANY INFORMATION

for the Year Ended 30 June 2025

| DIRECTOR: | D D A Tran

| REGISTERED OFFICE: | 280 Bishopsgate

| London

| EC2M 4AG

| REGISTERED NUMBER: | 12804340 (England and Wales)

| AUDITORS: | Oury Clark Chartered Accountants

| Statutory Auditors

| Herschel House

| 58 Herschel Street

| Slough

| Berkshire

| SL1 1PG

HARRISON-AI MEDICAL UK LTD (REGISTERED NUMBER: 12804340)

PREVIOUSLY KNOWN AS ANNALISE-AI UK LTD

BALANCE SHEET

30 June 2025

| 30.6.25 | 30.6.24 |

| Notes | £ | £ | £ | £ |

FIXED ASSETS

Tangible assets | 4 | 15,267 |  | 16,892 |  |

Investments | 5 | 123 |  | 123 |  |

15,390 |  | 17,015 |  |

CURRENT ASSETS

Debtors | 6 | 2,991,306 |  | 3,123,139 |  |

Cash at bank | 398,029 |  | 121,524 |  |

3,389,335 |  | 3,244,663 |  |

CREDITORS

Amounts falling due within one year | 7 | 2,516,667 |  | 1,229,536 |  |

NET CURRENT ASSETS | 872,668 |  | 2,015,127 |  |

TOTAL ASSETS LESS CURRENT LIABILITIES | 888,058 |  | 2,032,142 |  |

CREDITORS

Amounts falling due after more than one year | 8 | (587,316 | ) | (1,755,169 | ) |

PROVISIONS FOR LIABILITIES | (3,817 | ) | - |  |

NET ASSETS | 296,925 |  | 276,973 |  |

CAPITAL AND RESERVES

Called up share capital | 9 | 100 |  | 100 |  |

Other reserves | 10 | 104,023 |  | 100,244 |  |

Retained earnings | 10 | 192,802 |  | 176,629 |  |

SHAREHOLDERS' FUNDS | 296,925 |  | 276,973 |  |

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 19 February 2026 and were signed by:

D D A Tran - Director

HARRISON-AI MEDICAL UK LTD (REGISTERED NUMBER: 12804340)

PREVIOUSLY KNOWN AS ANNALISE-AI UK LTD

NOTES TO THE FINANCIAL STATEMENTS

for the Year Ended 30 June 2025

1. | STATUTORY INFORMATION

| Harrison-AI Medical UK Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. | ACCOUNTING POLICIES

| Basis of preparing the financial statements

| These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

| The financial statements have been prepared on the going concern basis in light of the fact that the ultimate parent company, Harrison-AI Pty Ltd (incorporated in Australia), will continue to provide financial support to the company for a period of 12 months and 1 day following the sign off of the audit report.

| Related party exemption

| The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

| Turnover

| Turnover is measured at fair value of the consideration received, excluding discounts, rebates, value added tax, and other sales tax.

| The company has two streams of turnover:

| 1. External sales revenue;

| 2. Intercompany sales.

| The company is a supplier of medical imaging software. External sales revenue is contract based and revenue is recognised over the time the customer has a right to access the software throughout the licence period. Revenue is recognised from the closest month starting the first day and ending on the last day in which coverage should end.

| Intercompany sales is a net-cost recharge to the parent company, Harrison-AI Medical Pty Ltd (previously known as Annalise-AI Pty Limited), in accordance with the cost-plus agreement. Turnover is wholly attributable to the principal activity of the company and is recognised when the relevant costs are incurred.

| Tangible fixed assets

| Tangible fixed assets are initially measured at cost and subsequently measured at cost, net of depreciation and any impairment losses.

| Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

| Plant and machinery - 33% on cost.

| Investments in subsidiaries

| Investments in subsidiary undertakings are recognised at cost less any impairment.

| Financial instruments

| Basic Financial Instruments as covered by Section 11 of FRS 102 are measured at amortised cost. The company does not have any Other Financial Instruments as covered by Section 12 of FRS 102.

HARRISON-AI MEDICAL UK LTD (REGISTERED NUMBER: 12804340)

PREVIOUSLY KNOWN AS ANNALISE-AI UK LTD

NOTES TO THE FINANCIAL STATEMENTS - continued

for the Year Ended 30 June 2025

2. | ACCOUNTING POLICIES - continued

| Taxation

| Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

| Current or deferred taxation assets and liabilities are not discounted.

| Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

| Deferred tax

| Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

| Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

| Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

| Foreign currencies

| Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

| Pension costs and other post-retirement benefits

| The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

| Share based payments

| Equity-settled transactions are awards of shares, or options over shares, that are provided to employees in exchange for the rendering of services.

| The cost of equity-settled transactions is measured at fair value on grant date. The fair value is estimated at the date of grant using a Black-Scholes option-pricing model. This fair value is based on the fair value of the underlying share, the exercise price, the risk free rate, the expected life of the option, the expected dividend yield and the volatility. Assumptions have been used in determining the fair value of the underlying share, the risk free rate, the expected life of the option, the dividend yield and the volatility. The volatility has been estimated by using historical volatilities of comparable listed companies.

| The cost of equity-settled transactions is recognised as an expense with a corresponding increase in equity over the vesting period. The cumulative charge to the income statement is calculated based on the grant date fair value of the award, the best estimate of the number of awards that are likely to vest and the expired portion of the vesting period. The amounts recognised in the income statement for the period is the cumulative amount calculated at each reporting date less amounts already recognised in previous periods.

3. | EMPLOYEES AND DIRECTORS

| The average number of employees during the year was 17 (2024 - 13 ) .

HARRISON-AI MEDICAL UK LTD (REGISTERED NUMBER: 12804340)

PREVIOUSLY KNOWN AS ANNALISE-AI UK LTD

NOTES TO THE FINANCIAL STATEMENTS - continued

for the Year Ended 30 June 2025

4. | TANGIBLE FIXED ASSETS

| Plant and

| machinery

| etc

£ |

| COST

| At 1 July 2024 | 27,558 |  |

| Additions | 8,949 |  |

| Disposals | (1,566 | ) |

| At 30 June 2025 | 34,941 |  |

| DEPRECIATION

| At 1 July 2024 | 10,666 |  |

| Charge for year | 10,356 |  |

| Eliminated on disposal | (1,348 | ) |

| At 30 June 2025 | 19,674 |  |

| NET BOOK VALUE

| At 30 June 2025 | 15,267 |  |

| At 30 June 2024 | 16,892 |  |

5. | FIXED ASSET INVESTMENTS

| Shares in

| group

| undertakings

£ |

| COST

| At 1 July 2024

| and 30 June 2025 | 123 |  |

| NET BOOK VALUE

| At 30 June 2025 | 123 |  |

| At 30 June 2024 | 123 |  |

6. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

| 30.6.25 |  | 30.6.24

£ | £ |

| Trade debtors | 798,303 |  | 1,382,605 |  |

| Amounts owed by group undertakings | 1,996,164 |  | 1,738,080 |  |

| Other debtors | 196,839 |  | 2,454 |  |

2,991,306 |  | 3,123,139 |  |

HARRISON-AI MEDICAL UK LTD (REGISTERED NUMBER: 12804340)

PREVIOUSLY KNOWN AS ANNALISE-AI UK LTD

NOTES TO THE FINANCIAL STATEMENTS - continued

for the Year Ended 30 June 2025

7. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

| 30.6.25 |  | 30.6.24

£ | £ |

| Trade creditors | 225,379 |  | 908 |  |

| Amounts owed to group undertakings | 1,074 |  | - |  |

| Tax | - |  | 32,070 |  |

| Social security and other taxes | 50,264 |  | 42,605 |  |

| VAT | 40,125 |  | 15,103 |  |

| Other creditors | 61,724 |  | 12,985 |  |

| Accruals and deferred income | 2,138,101 |  | 1,125,865 |  |

2,516,667 |  | 1,229,536 |  |

8. | CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR |

| 30.6.25 |  | 30.6.24

£ | £ |

| Accruals and deferred income | 587,316 |  | 1,755,169 |  |

9. | CALLED UP SHARE CAPITAL

| Allotted, issued and fully paid:

| Number: | Class: | Nominal | 30.6.25 |  | 30.6.24

| value: | £ | £ |

| 100 | Ordinary | £1 | 100 |  | 100 |  |

10. | RESERVES

| Retained |  | Other |

| earnings |  | reserves |  | Totals

£ | £ | £ |

| At 1 July 2024 | 176,629 |  | 100,244 |  | 276,873 |  |

| Profit for the year | 16,173 |  | 16,173 |  |

| Share based payment | - |  | 3,779 |  | 3,779 |  |

| At 30 June 2025 | 192,802 |  | 104,023 |  | 296,825 |  |

11. | DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006

| The Report of the Auditors was unqualified.

| Emma Florentin-Lee (Senior Statutory Auditor)

| for and on behalf of Oury Clark Chartered Accountants

| We would like to draw your attention to the following statement contained within our audit report as included within the full financial statements:-

| "Use of our report

| This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in a Report of the Auditors and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed."

HARRISON-AI MEDICAL UK LTD (REGISTERED NUMBER: 12804340)

PREVIOUSLY KNOWN AS ANNALISE-AI UK LTD

NOTES TO THE FINANCIAL STATEMENTS - continued

for the Year Ended 30 June 2025

12. | ULTIMATE CONTROLLING PARTIES

| The immediate parent company is Harrison-AI Medical Pty Ltd (formerly known as Annalise-AI Pty Ltd), a company incorporated in Australia with registered office at Level P, 24 Campbell Street, Sydney NSW 2000, Australia.

| The ultimate parent company is Harrison-AI Pty Ltd, a company incorporated in Australia with registered office at Level P, 24 Campbell Street, Sydney NSW 2000, Australia. This is the largest and smallest group for which consolidated accounts are produced. Consolidated accounts are not publicly available.

13. | SHARE-BASED PAYMENT TRANSACTIONS

| The ultimate parent company, Harrison-AI Pty Ltd, a company registered in Australia, has reserved shares of stock for issuance as stock options under its 2020 Share Option Plan (the "Plan").

| The Plan is equity settled and provides for grants of incentive stock options to employees of the company. Options under the Plan are granted at the estimated fair value of the shares on the date of grant as determined by the Board of Directors. The maximum term of options granted under the Plan is 7 years from the date of grant. Options under the Plan generally vest over 4 years.

| Options under the Plan are generally exercisable when vested and subject to such terms, conditions, performance criteria, and restrictions as determined by the Board of Directors and set forth in the related option agreements.

| There were 212,346 options outstanding at the beginning of the period. There were no options forfeited, granted, exercised or expired in the period. There were 212,346 options outstanding and exercisable at the end of the period.

| The weighted average exercise price of options outstanding at the year end was $1.08, and the weighted average remaining contractual life was 2.34 years.

| During the year, share options expense of £3,779 (2024: Nil) was recognised . The total cumulative charge recognised to date is £104,023 (2024: £100,244).

| The Company will be liable to employer's national insurance contributions should the options be exercised in the future. The timing and value of this is currently not known. The Company has a joint agreement in place with employees holding options, and so there is a possibility that any contingent liability would be recovered.